Guerbet — Earnings Release 2008

Nov 12, 2008

P R E S S R E L E A S E

2008 third-quarter sales

Villepinte, 12 November 2008

Consolidated group sales (IFRS):

In thousands of euros	2008	2007	Change
First quarter …………………………………	75,573	72,841	+ 3.8%
Second quarter ………………………………	81,376	79,165	+ 2.8%
Third quarter …………………………………	79,160	74,539	+ 6.2%
First nine months ………………………	236,109	226,545	+ 4.2%

Consolidated sales by region

In thousands of euros	2008	2007	Change
European subsidiaries………….……………	186,969	177,320	+ 5.4%
Other markets …………………………………	49,140	49,225	- 0.2%
First nine months ….………………….	236,109	226,545	+ 4.2%

2008 third-quarter sales and outlook

Xenetix delivered particularly robust sales in the third quarter, expanding 15.5% in volume and 8.4% in value over the same period last year.

As a result, for the first nine months of 2008 Xenetix grew in volume 1.1% over the equivalent prior-year period and limited the total contraction in sales over this period to 2.8%.

Dotarem also achieved significant gains in the third quarter over the prior year of respectively 16% in volume and 12.5% in value. For the first nine months, this performance contributed to total gains respectively of 29.6% and 24.1% on this basis.

Guerbet has continued to strengthen its commercial positions in its key European markets and notably in Germany and France.

The confirmation of positive sales trends for Xenetix and Dotarem should enable the Group to maintain satisfactory level of profitability.

Contact: Finance Department. Tel: +33 (0) 1 45 91 50 11